340B Drug Pricing Program

The Department of Health and Human Services today issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program. 
As the industry “that generates higher profit margins than any other,” Big Pharma continues to price gouge consumers for life-saving drugs. One thing the pharmaceutical industry is not entitled to, however, is its own set of facts.
The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
The AHA urges the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
On Nov. 2, the Centers for Medicare & Medicaid Services issued its calendar year 2019 outpatient prospective payment system /ambulatory surgical center final rule. In addition to standard updates, the rule expands Medicare “site-neutral” payment policies and changes the payment policies for…
Facing deadlines for responding to the lawsuit brought by the AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems, the Health Resources and Services Administration proposes a Jan. 1 compliance date for its final rule on 340B drug…
A federal court today denied the Department of Health and Human Services’ motion for a stay in a lawsuit challenging the excessive delay in the effective date for the 340B price transparency rule.
The Department of Health and Human Services today proposed implementing on Jan. 1 its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.